drugset / Trial / NCT04508400
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose is to evaluate the effectiveness and safety of fosaprepitant plus ondansetron with dexamethasone or placebo plus ondansetron with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HE multi-day chemotherapy in children with solid tumors.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-06-22
- Completion
- 2023-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosaprepitant | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Background | Ondansetron | Other / unclassified | — | Intravenous |